Sino Biopharmaceutical (1177) Stock Statistics & Valuation Metrics

Sino Biopharmaceutical has a market cap or net worth of HK$97.03B. The enterprise value is HK$92.95B.

Sino Biopharmaceutical has 18,745,367,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sino Biopharmaceutical’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 8.57%.

The current PE Ratio of Sino Biopharmaceutical is ―. Sino Biopharmaceutical’s PEG ratio is -1.25.

In the last 12 months, Sino Biopharmaceutical had revenue of 31.01B and earned 2.28B in profits. Earnings per share was 0.13.

In the last 12 months, operating cash flow was 3.16B and capital expenditures -270.85M, giving a free cash flow of 2.89B billion.

Sino Biopharmaceutical pays an annual dividend of HK$0.05, resulting in a dividend yield of 1.4%

Sino Biopharmaceutical upcoming earnings date is Aug 26, 2026, TBA (Confirmed).

Sino Biopharmaceutical as a current ratio of 1.37, with Debt / Equity ratio of 52.39%

In the past 12 months, Sino Biopharmaceutical has paid 1.59B in taxes.

Sino Biopharmaceutical EV to EBITDA ratio is 13.94, with an EV/FCF ratio of 14.31.

Sino Biopharmaceutical has HK$19.82B in cash and marketable securities with HK$11.96B in debt, giving a net cash position of HK$7.87B billion.

Gross margin is 82.02%, with operating margin of 21.40%, and net profit margin of 7.36%.

The average price target for Sino Biopharmaceutical is HK$8.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy